МДМА (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "МДМА" in Serbian language version.

refsWebsite

Global rank Serbian rank

7doi.org

2^nd place

4^th place

7nih.gov

4^th place

8^th place

5erowid.org

3,887^th place

2,929^th place

4web.archive.org

1^st place

1google.ca

838^th place

391^st place

1europa.eu

68^th place

107^th place

1webcitation.org

24^th place

56^th place

1dot.gov

1,690^th place

5,522^nd place

1springer.com

274^th place

510^th place

1nature.com

234^th place

287^th place

1drugabuse.gov

6,166^th place

low place

1who.int

195^th place

154^th place

1ecstasy.org

low place

1addictionjournal.org

low place

1betweenthelines.net.au

low place

1betterhealth.vic.gov.au

low place

1mydr.com.au

low place

1archive.org

6^th place

5^th place

addictionjournal.org

Addiction (February 2011) "New study finds no cognitive impairment among ecstasy users" Архивирано на сајту Wayback Machine (12. јул 2011)

archive.org

Verheyden SL, Henry JA, Curran HV (2003). „Acute, sub-acute and long-term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users”. Hum Psychopharmacol. 18 (7): 507—17. PMID 14533132. doi:10.1002/hup.529.

betterhealth.vic.gov.au

„Ecstasy”. betterhealth.vic.gov.au. Архивирано из оригинала 26. 04. 2014. г. Приступљено 25. 5. 2010.

betweenthelines.net.au

„Ecstasy basics”. betweenthelines.net.au. Архивирано из оригинала 28. 10. 2012. г. Приступљено 25. 5. 2010.

doi.org

Carvalho M, Carmo H, Costa VM, Capela JP, Pontes H, Remião F, Carvalho F, Bastos Mde L (2012). „Toxicity of amphetamines: an update”. Arch. Toxicol. 86 (8): 1167—1231. PMID 22392347. doi:10.1007/s00204-012-0815-5.
Luciano, Randy L.; Perazella, Mark A. (25. 3. 2014). „Nephrotoxic effects of designer drugs: synthetic is not better!”. Nature Reviews Nephrology. 10 (6): 314—324. doi:10.1038/nrneph.2014.44. Приступљено 2. 12. 2014.
Bernschneider-Reif S, Oxler F, Freudenmann RW (2006). „The Origin of MDMA ("Ecstasy")--Separating the Facts From the Myths.”. Pharmazie. 61 (11): 966—972. PMID 17152992. doi:10.1111/j.1360-0443.2006.01511.x.
Liechti ME, Gamma A, Vollenweider FX (2001). „Gender Differences in the Subjective Effects of MDMA”. Psychopharmacology. 154 (2): 161—168. PMID 11314678. doi:10.1007/s002130000648.
Hardman HF, Haavik CO, Seevers MH (1973). „Relationship of the Structure of Mescaline and Seven Analogs to Toxicity and Behavior in Five Species of Laboratory Animals”. Toxicology Applied Pharmacology. 25 (2): 299—309. PMID 4197635. doi:10.1016/S0041-008X(73)80016-X.
Verheyden SL, Henry JA, Curran HV (2003). „Acute, sub-acute and long-term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users”. Hum Psychopharmacol. 18 (7): 507—17. PMID 14533132. doi:10.1002/hup.529.
Verheyden SL, Maidment R, Curran HV (2003). „Quitting ecstasy: an investigation of why people stop taking the drug and their subsequent mental health”. J. Psychopharmacol. (Oxford). 17 (4): 371—8. PMID 14870948. doi:10.1177/0269881103174014.

dot.gov

nhtsa.dot.gov

„Methylenedioxymethamphetamine (MDMA, ecstasy)”. Drugs and Human Performance Fact Sheets. National Highway Traffic Safety Administration. Архивирано из оригинала 31. 5. 2012. г. Приступљено 19. 5. 2010.

drugabuse.gov

„DrugFacts: MDMA (Ecstasy or Molly)”. National Institute on Drug Abuse. Архивирано из оригинала 03. 12. 2014. г. Приступљено 2. 12. 2014.

ecstasy.org

E for Ecstasy by Nicholas Saunders, Appendix 1: Reference Section. Ecstasy.org. Приступљено 2011-06-11.

erowid.org

Bernschneider-Reif S, Oxler F, Freudenmann RW (2006). „The Origin of MDMA ("Ecstasy")--Separating the Facts From the Myths.”. Pharmazie. 61 (11): 966—972. PMID 17152992. doi:10.1111/j.1360-0443.2006.01511.x.
Liechti ME, Gamma A, Vollenweider FX (2001). „Gender Differences in the Subjective Effects of MDMA”. Psychopharmacology. 154 (2): 161—168. PMID 11314678. doi:10.1007/s002130000648.
Erowid (September 2001). Short-Term Side Effects of MDMA.
Hardman HF, Haavik CO, Seevers MH (1973). „Relationship of the Structure of Mescaline and Seven Analogs to Toxicity and Behavior in Five Species of Laboratory Animals”. Toxicology Applied Pharmacology. 25 (2): 299—309. PMID 4197635. doi:10.1016/S0041-008X(73)80016-X.
„MDMA Basics”. erowid.org. Приступљено 25. 5. 2010.

europa.eu

emcdda.europa.eu

„Methylenedioxymethamphetamine (MDMA or 'Ecstasy')”. EMCDDA. European Monitoring Centre for Drugs and Drug Addiction. Приступљено 17. 10. 2014.

google.ca

books.google.ca

Palmer, Robert B. (2012). Medical toxicology of drug abuse : synthesized chemicals and psychoactive plants. Hoboken, N.J.: John Wiley & Sons. стр. 139. ISBN 9780471727606.

mydr.com.au

„Ecstasy: effects on the body”. ydr.com.au. Приступљено 25. 5. 2010.

nature.com

Luciano, Randy L.; Perazella, Mark A. (25. 3. 2014). „Nephrotoxic effects of designer drugs: synthetic is not better!”. Nature Reviews Nephrology. 10 (6): 314—324. doi:10.1038/nrneph.2014.44. Приступљено 2. 12. 2014.

nih.gov

ncbi.nlm.nih.gov

Carvalho M, Carmo H, Costa VM, Capela JP, Pontes H, Remião F, Carvalho F, Bastos Mde L (2012). „Toxicity of amphetamines: an update”. Arch. Toxicol. 86 (8): 1167—1231. PMID 22392347. doi:10.1007/s00204-012-0815-5.
Bernschneider-Reif S, Oxler F, Freudenmann RW (2006). „The Origin of MDMA ("Ecstasy")--Separating the Facts From the Myths.”. Pharmazie. 61 (11): 966—972. PMID 17152992. doi:10.1111/j.1360-0443.2006.01511.x.
Liechti ME, Gamma A, Vollenweider FX (2001). „Gender Differences in the Subjective Effects of MDMA”. Psychopharmacology. 154 (2): 161—168. PMID 11314678. doi:10.1007/s002130000648.
Hardman HF, Haavik CO, Seevers MH (1973). „Relationship of the Structure of Mescaline and Seven Analogs to Toxicity and Behavior in Five Species of Laboratory Animals”. Toxicology Applied Pharmacology. 25 (2): 299—309. PMID 4197635. doi:10.1016/S0041-008X(73)80016-X.
Verheyden SL, Henry JA, Curran HV (2003). „Acute, sub-acute and long-term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users”. Hum Psychopharmacol. 18 (7): 507—17. PMID 14533132. doi:10.1002/hup.529.
Verheyden SL, Maidment R, Curran HV (2003). „Quitting ecstasy: an investigation of why people stop taking the drug and their subsequent mental health”. J. Psychopharmacol. (Oxford). 17 (4): 371—8. PMID 14870948. doi:10.1177/0269881103174014.

toxnet.nlm.nih.gov

„3,4-Methylenedioxymethamphetamine”. Hazardous Substances Data Bank. National Library of Medicine. 28. 8. 2008. Приступљено 22. 11. 2014.

springer.com

link.springer.com

Freye, Enno (2009). „Pharmacological Effects of MDMA in Man”. Pharmacology and Abuse of Cocaine, Amphetamines, Ecstasy and Related Designer Drugs. Springer Netherlands. стр. 151—160. ISBN 978-90-481-2448-0. Приступљено 18. 6. 2015.

web.archive.org

„DrugFacts: MDMA (Ecstasy or Molly)”. National Institute on Drug Abuse. Архивирано из оригинала 03. 12. 2014. г. Приступљено 2. 12. 2014.
Addiction (February 2011) "New study finds no cognitive impairment among ecstasy users" Архивирано на сајту Wayback Machine (12. јул 2011)
„Ecstasy basics”. betweenthelines.net.au. Архивирано из оригинала 28. 10. 2012. г. Приступљено 25. 5. 2010.
„Ecstasy”. betterhealth.vic.gov.au. Архивирано из оригинала 26. 04. 2014. г. Приступљено 25. 5. 2010.

webcitation.org

„Methylenedioxymethamphetamine (MDMA, ecstasy)”. Drugs and Human Performance Fact Sheets. National Highway Traffic Safety Administration. Архивирано из оригинала 31. 5. 2012. г. Приступљено 19. 5. 2010.

who.int

whqlibdoc.who.int

22nd report of the Expert Committee on Drug Dependence World Health Organization, 1985], Приступљено 11. 4. 2013.